Esperion Projects FY2025 U.S. Net Product Sales Growth Of 35% To 38%; Stock Up

Esperion reported strong preliminary full-year 2025 results with U.S. net product sales of $156M–$160M (up 35%–38% vs. 2024) and total preliminary revenue of $400M–$408M (up 20%–23%; ~55%–59% excluding one-time milestones); Q4 retail prescription equivalents rose 34% YoY and 11.3% sequentially. The company ended 2025 with approximately $168M in cash, expects 2026 operating expenses of $210M–$245M, anticipates regulatory approvals in Canada, Israel and Australia this year, and rolled out a long-term Vision 2040 strategy as it continues U.S. commercial expansion and pipeline development.

Analysis

Market structure: Esperion (ESPR) is the direct beneficiary — rising U.S. net product sales ($156–160M in 2025) and 34% YoY Rx growth in Q4 signal expanding physician adoption and reimbursement that can erode share of higher‑cost PCSK9 injectables and incrementally pressure their pricing power. Payers and large PBMs win via a cheaper oral alternative; large statin/ezetimibe incumbents face modest margin pressure but limited displacement risk given statins’ dominant role. Cross‑asset: idiosyncratic to equities — minimal FX or commodity impact; short‑dated corporate credit spreads for ESPR peers could tighten if broader biotech sentiment improves, while options IV on ESPR should compress after major catalysts.

Risk assessment: Key tail risks are regulatory/safety setbacks, adverse payer formulary moves, or inability to convert global approvals; a material solvency risk exists because cash ~$168M vs FY26 OpEx guide $210–245M implies dependence on near‑term revenue or funding (liquidity pressure within 12 months if growth stalls). Timeframe split: immediate (days) — post‑earnings momentum; short (weeks–months) — regulatory decisions and reimbursement updates; long (quarters–years) — Vision 2040 execution, pipeline readouts. Hidden dependency: growth relies on continued PBM coverage expansion; reversal there hits trajectory and valuation.

Trade implications: Tactical long conviction with risk management — establish a measured 2–3% long position in ESPR targeting 40–60% upside over 6–12 months driven by international approvals and adoption; hedge sector beta via a short XBI position. Preferred options: buy a 6–9 month call spread (buy 4.00 / sell 8.00 strikes) to leverage catalysts with defined cost and capped risk; size to 1% notional. If cash falls below $100M or company issues negative 2026 revenue guidance, reduce exposure by 50% immediately.

Contrarian angles: Consensus underestimates balance‑sheet risk and overestimates sustainable pricing power — milestones inflated 2025 revenue (ex‑one‑time) and Vision 2040 is aspirational with high execution risk. Historical parallels: oral non‑statin launches (ezetimibe, early PCSK9 uptake) show front‑loaded adoption then payer tightening; unintended consequence — aggressive global expansion could force equity raises and dilute upside. A downside catalyst (safety/coverage reversal) could compress share price >50% quickly, meaning entry sizing and hard stops are essential.

Key Decisions for Investors

• Establish a 2–3% long position in ESPR (ticker: ESPR) at or below $4.25, target 40–60% upside in 6–12 months driven by expected international approvals and continued U.S. Rx growth; use a hard stop‑loss at 30% below entry (~$2.98) to limit downside from regulatory or reimbursement shocks.
• Purchase a defined‑risk call spread sized to ~1% portfolio risk: buy 6–9 month ESPR 4.00 / 8.00 call spread (debit) ahead of upcoming regulatory and commercial catalysts; unwind if spread reaches 70% of max profit or at 9 months.
• Implement a relative value hedge: long ESPR (2% portfolio) paired with a short XBI position sized to neutralize ~70% beta (short 1.2% notional of XBI) to isolate idiosyncratic commercialization upside while hedging sector drawdowns over next 3–12 months.
• Trigger‑based risk control: if company cash falls below $100M, or FY‑2026 revenue guidance revises below midpoint of implied $400M run‑rate within 30 days, reduce net exposure to ESPR by 50% and reassess after the next quarterly report.